Scott J. Diede

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

29h-index6.5kcitations89works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(51), CAR-T cell therapy research(46), Melanoma and MAPK Pathways(24), Immunotherapy and Immune Responses(14), Cutaneous Melanoma Detection and Management(10)

Publications88 total

Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma
Annals of Oncology·2025· 4 cited
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study
The Lancet·2025· 13 cited
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibroma (PN): Primary analysis of KOMET (NCT04924608), a phase 3, international, randomized, placebo-controlled study.
Journal of Clinical Oncology·2025
Phase 1/2 study of zilovertamab vedotin in pediatric and young adult hematologic malignancies or solid tumors (LIGHTBEAM-U01A).
Journal of Clinical Oncology·2025
Abstract CT119: Zilovertamab vedotin in pediatric and young adult hematologic malignancies or solid tumors: Phase 1/2 LIGHTBEAM-U01A study
Cancer Research·2025
Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.
Journal of Clinical Oncology·2024· 4 cited
Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.
Journal of Clinical Oncology·2024· 4 cited
1109P Second-line pembrolizumab (pembro) in Chinese patients (pts) with advanced melanoma: Long-term follow-up of the phase I KEYNOTE-151 study
Annals of Oncology·2023Open Access
Burden and Risk Factors of Brain Metastases in Melanoma: A Systematic Literature Review
Cancers·2022· 15 citedOpen Access
Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases
Frontiers in Oncology·2022· 10 citedOpen Access
Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study
Frontiers in Immunology·2022· 25 citedOpen Access
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Journal of Clinical Oncology·2022· 243 citedOpen Access
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Journal of Clinical Oncology·2022· 124 cited
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
Journal of Clinical Oncology·2022· 4 cited
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in <i>BRAF</i><sup>V600E/K</sup>-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.
Journal of Clinical Oncology·2022· 8 cited
Current Treatment Approaches and Global Consensus Guidelines for Brain Metastases in Melanoma
Frontiers in Oncology·2022· 20 citedOpen Access
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation
European Journal of Cancer·2021· 10 cited
383 Durable responses with intratumoral electroporation of plasmid interleukin 12 plus pembrolizumab in patients with advanced melanoma progressing on an anti-PD-1 antibody: updated data from keynote 695
Regular and Young Investigator Award Abstracts·2021· 3 citedOpen Access
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
European Journal of Cancer·2021· 24 citedOpen Access
1037O MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB–IVM1c melanoma (MEL)
Annals of Oncology·2021· 56 cited
page 1 of 5Next →

Frequent Co-authors

Georgina V. Long(16), Antoni Ribas(12), F. Stephen Hodi(10), Omid Hamid(9), Stephen J. Tapscott(9), Reinhard Dummer(8), Thomas F. Gajewski(7), Ana Arance(7), Matteo S. Carlino(7), Caroline Robert(7), Scot Ebbinghaus(7), Igor Puzanov(5), Adil Daud(5), Victoria Atkinson(5), Jacob Schachter(5), John M. Kirkwood(4), Jean‐Jacques Grob(4), Lev Demidov(4), James R. Anderson(4), Tara C. Mitchell(4)